LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis GBX 126 -2.00 (-1.56%) (As of 09/6/2024 11:46 AM ET) Add Compare Share Share Today's Range 126▼ 12850-Day Range 119▼ 13452-Week Range 82▼ 136Volume20,000 shsAverage Volume97,556 shsMarket Capitalization£106.42 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 160 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Diaceutics alerts: Email Address Diaceutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside27.0% UpsideGBX 160 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares£15,264 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 stars 3.5 Analyst's Opinion Consensus RatingDiaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDiaceutics has only been the subject of 1 research reports in the past 90 days.Read more about Diaceutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DXRX. Previous Next 0.0 Dividend Strength Dividend YieldDiaceutics does not currently pay a dividend.Dividend GrowthDiaceutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DXRX. Previous Next 2.9 News and Social Media Coverage News SentimentDiaceutics has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Diaceutics this week, compared to 0 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Diaceutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought £152.64 in company stock and sold GBX 0 in company stock.Percentage Held by Insiders34.30% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.31% of the stock of Diaceutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Diaceutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Diaceutics is -6,300.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Diaceutics is -6,300.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaceutics has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Diaceutics Stock (LON:DXRX)Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.Read More DXRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXRX Stock News HeadlinesAugust 31, 2024 | insidertrades.comInsider Buying: Diaceutics PLC (LON:DXRX) Insider Buys 113 Shares of StockSeptember 1, 2024 | americanbankingnews.comNick Roberts Buys 113 Shares of Diaceutics PLC (LON:DXRX) StockSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 26, 2023 | finance.yahoo.comDiaceutics (LON:DXRX) shareholders have endured a 41% loss from investing in the stock three years agoOctober 26, 2023 | finance.yahoo.comCalculating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)October 26, 2023 | finance.yahoo.comDiaceutics First Half 2023 Earnings: EPS Beats ExpectationsApril 20, 2023 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies AheadApril 20, 2023 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 17, 2023 | marketwatch.comDiaceutics 2022 Pretax Profit Rose on Growing DemandMarch 13, 2023 | marketwatch.comDiaceutics Suspends Share Trading as SVB Closure Restricts Access to Its FundsMarch 10, 2023 | finance.yahoo.comThose who invested in Diaceutics (LON:DXRX) a year ago are up 13%January 28, 2023 | finance.yahoo.comBroker Revenue Forecasts For Diaceutics PLC (LON:DXRX) Are Surging HigherJanuary 27, 2023 | lse.co.ukTRADING UPDATES: Diaceutics wins two deals; Faron proposes placingDecember 9, 2022 | finance.yahoo.comAn Intrinsic Calculation For Diaceutics PLC (LON:DXRX) Suggests It's 40% UndervaluedNovember 28, 2022 | msn.comDanske Bank supported the purchase of the new building at Kings Hall Life Sciences ParkSeptember 29, 2022 | finance.yahoo.comEdited Transcript of DXRX.L earnings conference call or presentation 28-Sep-22 12:00pm GMTSeptember 16, 2022 | nz.finance.yahoo.comDEWA and WGEO Complete Preparations for 8th Edition of the World Green Economy SummitSee More Headlines Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:DXRX CUSIPN/A CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 160 High Stock Price TargetGBX 160 Low Stock Price TargetGBX 160 Potential Upside/Downside+27.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.02) Trailing P/E RatioN/A Forward P/E Ratio100.45 P/E GrowthN/ANet Income£-1,750,000.00 Net Margins-7.37% Pretax MarginN/A Return on Equity-4.19% Return on Assets-3.99% Debt Debt-to-Equity Ratio2.95 Current Ratio6.40 Quick Ratio9.92 Sales & Book Value Annual Sales£23.70 million Price / Sales4.49 Cash FlowGBX 40.39 per share Price / Cash Flow3.12 Book ValueGBX 48 per share Price / Book2.63Miscellaneous Outstanding Shares84,460,000Free FloatN/AMarket Cap£106.42 million OptionableNot Optionable Beta0.58 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Ryan Keeling (Age 42)CEO & Director Comp: $334.27kMr. Peter Keeling (Age 64)Founder & Executive Director Comp: $363.24kMr. Nicholas Stewart Roberts (Age 42)CFO & Director Comp: $180.37kMs. Julie BrowneChief Operating OfficerMs. Gillian ShawGeneral CounselMs. Norma ThompsonGlobal Head of Human ResourcesMr. Jordan ClarkChief Commercial OfficerMs. Susanne MunkstedChief Precision Medicine OfficerMs. Jillian BeggsChief Commercial OfficerMs. Marieke HoefsmitSenior Director & Head of Data Delivery NetherlandsMore ExecutivesKey CompetitorsANGLELON:AGLAbingdon HealthLON:ABDXYourgene HealthLON:YGENVerici DxLON:VRCIgenedriveLON:GDRView All CompetitorsInsidersNick RobertsBought 113 shares on 8/28/2024Total: £15,142.00 ($134.00/share)Nick RobertsBought 122 shares on 6/28/2024Total: £122.00 ($1.00/share)Graham PatersonBought 39,934 shares on 5/22/2024Total: £5.15 M ($129.00/share)Peter KeelingSold 750,000 sharesTotal: £76.50 M ($102.00/share)Graham PatersonBought 33,564 shares on 3/6/2024Total: £3.32 M ($99.00/share)View All Insider Transactions DXRX Stock Analysis - Frequently Asked Questions How have DXRX shares performed this year? Diaceutics' stock was trading at GBX 87 at the beginning of 2024. Since then, DXRX shares have increased by 44.8% and is now trading at GBX 126. View the best growth stocks for 2024 here. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DXRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.